Drug Trial Radar · NCT07457580
Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs)
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Mar 16, 2026
Primary completion
Nov 30, 2026
Study completion Nov 30, 2026
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Mar 9, 2026
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multi-country, multi-center retrospective observational cohort study based on secondary data collected via chart review, with the aim of describing patient characteristics (including relevant comorbidities), monitoring and treatment practices related to Type 1 diabetes mellitus (T1D) progression, and time to T1D progression in participants who received teplizumab as part of Managed Access Programs (MAPs). This study design was chosen in order to gain rapid insight into the current use of teplizumab in clinical practice and the characteristics of patients who received the treatment.
Conditions
- Type 1 Diabetes
Interventions
TeplizumabDrug
This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practice.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Participant demographics at teplizumab initiationTime frame: At Day 1 (first dose of teplizumab)
- Participants' family history of T1D and autoimmune diseasesTime frame: At Day 1 (first dose of teplizumab)
- Presence of T1D susceptibility genesTime frame: At Day 1 (first dose of teplizumab)
- Presence of T1D susceptibility genesTime frame: At Day 1 (first dose of teplizumab)
- Participants' medical historyTime frame: From 6 months prior to the first dose of teplizumab (teplizumab initiation) (or the earliest date of all data contributing to Stage 2 T1D diagnosis, whichever is earlier) up to medical records abstraction date, approximately 3-4 years
Locations
16 sites in 6 countries. Site status is shown where the registry gives one.
Investigational Site Number: 0560001
Leuven, Belgium · Completed
Investigational Site Number: 2500001
Bron, France · Completed
Investigational Site Number: 2500003
Paris, France · Completed
Investigational Site Number: 2500002
Paris, France · Completed
Investigational Site Number: 2760003
Augsburg, Germany · Recruiting
Investigational Site Number: 2760002
Frankfurt, Germany · Completed
Investigational Site Number: 2760001
Hanover, Germany · Completed
Investigational Site Number: 2760004
Munich, Germany · Recruiting
Investigational Site Number: 3800001
Ancona, Italy · Completed
Investigational Site Number: 3800003
Palermo, Italy · Completed
Investigational Site Number: 3800002
Verona, Italy · Completed
Investigational Site Number: 7240001
Madrid, Spain · Completed
Investigational Site Number: 7240002
Madrid, Spain · Completed
Investigational Site Number: 7240003
Zaragoza, Spain · Completed
Investigational Site Number: 8260001
Birmingham, United Kingdom · Completed
Investigational Site Number: 8260002
London, United Kingdom · Completed
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.